Catalyst (CPRX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Catalyst Pharmaceutical (CPRX) reported Q2 2025 revenue of $146.56 million and EPS of $0.68, significantly surpassing analyst consensus estimates by 5.3% and 17.24% respectively. While total product revenue exceeded expectations, driven by strong performance in FYCOMPA ($34.33M vs. $25.92M est.) and AGAMREE ($27.36M vs. $25.12M est.) sales, FIRDAPSE revenue ($84.85M vs. $88.01M est.) slightly missed, and license revenue saw a substantial year-over-year decline. The company's stock has outperformed the broader market recently, reflecting a positive near-term outlook with a Zacks Rank #2 (Buy).

Analysis

Catalyst Pharmaceutical delivered a robust second quarter for 2025, significantly outperforming analyst expectations on both revenue and earnings. The company reported total revenue of $146.56 million, a 19.4% year-over-year increase that surpassed the Zacks Consensus Estimate by 5.3%. More impressively, earnings per share of $0.68 represented a 17.24% positive surprise against a consensus of $0.58. A deeper look into the revenue composition reveals a strategic shift in growth drivers. While the overall product revenue beat estimates, this was primarily fueled by the strong performance of FYCOMPA and AGAMREE, which generated $34.33 million and $27.36 million respectively, both exceeding their forecasts. This outperformance successfully compensated for a slight miss in the company's largest product, FIRDAPSE, which posted revenue of $84.85 million against an estimate of $88.01 million. The stock's recent performance, a 7.1% gain in the past month, has substantially outpaced the S&P 500, reflecting investor confidence likely bolstered by these strong headline figures and a Zacks Rank #2 (Buy) designation.

Key Decisions for Investors

• The significant top-line and EPS beats validate the company's growth strategy, with the strong revenue contribution from FYCOMPA and AGAMREE signaling successful portfolio expansion beyond its primary product.
• Investors should closely monitor the performance of the core product, FIRDAPSE, as its slight revenue miss, while offset by newer products this quarter, remains a key variable for future growth projections.
• Given the stock's recent outperformance and the positive analyst rating, the results support a continued holding, but new investors should weigh the strength of the diversified growth against the slight underperformance of the legacy product before initiating a position.